Radioimmunotherapy for lymphoma - analysis of clinical trials and treatment algorithms
Ibritumomab, an (90)Yttrium ((90)Y) labelled radioimmunoconjugate, is registered in Europe to treat follicular lymphomas. Its mode of action combines the selectivity of monoclonal antibodies with the efficiency of radiotherapy, making it a unique and useful therapeutic agent. This paper is for haema...
Gespeichert in:
| Veröffentlicht in: | Nuclear medicine review. Central & Eastern Europe 2007, Vol.10 (2), p.110-115 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 115 |
|---|---|
| container_issue | 2 |
| container_start_page | 110 |
| container_title | Nuclear medicine review. Central & Eastern Europe |
| container_volume | 10 |
| creator | Jurczak, Wojciech Hubalewska-Dydejczyk, Alicja Giza, Agnieszka Sowa-Staszczak, Anna Huszno, Bohdan Skotnicki, Aleksander B |
| description | Ibritumomab, an (90)Yttrium ((90)Y) labelled radioimmunoconjugate, is registered in Europe to treat follicular lymphomas. Its mode of action combines the selectivity of monoclonal antibodies with the efficiency of radiotherapy, making it a unique and useful therapeutic agent. This paper is for haemato-oncologists with a decent practice in lymphoma therapy, who have not yet used ibritumomab themselves. It summarizes clinical trials with radioimmunotherapy, indicating clinical situations where it may be specifically useful. |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_70074756</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>70074756</sourcerecordid><originalsourceid>FETCH-LOGICAL-p209t-cbc89e8fda92ed1329772feec6c964ec020c2913f7f4b90407f090f57a614c663</originalsourceid><addsrcrecordid>eNo1kE1LxDAURbNQnHH0L0hW7govaZs0Sxn8ggFB1G3JpC9OJGlqki767x1xXN0L53AX94ysWQuiUqKDFbnM-QugbThnF2TFOs47zsSafLzqwUUXwjzGcsCkp4XamKhfwnSIQdOK6lH7JbtMo6XGu9EZ7WlJTvt8ZMOxoi4Bx0K1_4zJlUPIV-TcHjlen3JD3h_u37ZP1e7l8Xl7t6smDqpUZm86hZ0dtOI4sJorKblFNMIo0aABDoYrVltpm72CBqQFBbaVWrDGCFFvyO3f7pTi94y59MFlg97rEeOcewkgG9n-ijcncd4HHPopuaDT0v8_Uf8ACllagQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>70074756</pqid></control><display><type>article</type><title>Radioimmunotherapy for lymphoma - analysis of clinical trials and treatment algorithms</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Jurczak, Wojciech ; Hubalewska-Dydejczyk, Alicja ; Giza, Agnieszka ; Sowa-Staszczak, Anna ; Huszno, Bohdan ; Skotnicki, Aleksander B</creator><creatorcontrib>Jurczak, Wojciech ; Hubalewska-Dydejczyk, Alicja ; Giza, Agnieszka ; Sowa-Staszczak, Anna ; Huszno, Bohdan ; Skotnicki, Aleksander B</creatorcontrib><description>Ibritumomab, an (90)Yttrium ((90)Y) labelled radioimmunoconjugate, is registered in Europe to treat follicular lymphomas. Its mode of action combines the selectivity of monoclonal antibodies with the efficiency of radiotherapy, making it a unique and useful therapeutic agent. This paper is for haemato-oncologists with a decent practice in lymphoma therapy, who have not yet used ibritumomab themselves. It summarizes clinical trials with radioimmunotherapy, indicating clinical situations where it may be specifically useful.</description><identifier>ISSN: 1506-9680</identifier><identifier>PMID: 18228216</identifier><language>eng</language><publisher>Poland</publisher><subject>Algorithms ; Antibodies, Monoclonal - therapeutic use ; Clinical Trials as Topic - trends ; Decision Support Systems, Clinical ; Europe ; Humans ; Lymphoma - radiotherapy ; Radioimmunotherapy - trends ; Radiopharmaceuticals - therapeutic use</subject><ispartof>Nuclear medicine review. Central & Eastern Europe, 2007, Vol.10 (2), p.110-115</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,4010</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18228216$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jurczak, Wojciech</creatorcontrib><creatorcontrib>Hubalewska-Dydejczyk, Alicja</creatorcontrib><creatorcontrib>Giza, Agnieszka</creatorcontrib><creatorcontrib>Sowa-Staszczak, Anna</creatorcontrib><creatorcontrib>Huszno, Bohdan</creatorcontrib><creatorcontrib>Skotnicki, Aleksander B</creatorcontrib><title>Radioimmunotherapy for lymphoma - analysis of clinical trials and treatment algorithms</title><title>Nuclear medicine review. Central & Eastern Europe</title><addtitle>Nucl Med Rev Cent East Eur</addtitle><description>Ibritumomab, an (90)Yttrium ((90)Y) labelled radioimmunoconjugate, is registered in Europe to treat follicular lymphomas. Its mode of action combines the selectivity of monoclonal antibodies with the efficiency of radiotherapy, making it a unique and useful therapeutic agent. This paper is for haemato-oncologists with a decent practice in lymphoma therapy, who have not yet used ibritumomab themselves. It summarizes clinical trials with radioimmunotherapy, indicating clinical situations where it may be specifically useful.</description><subject>Algorithms</subject><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Clinical Trials as Topic - trends</subject><subject>Decision Support Systems, Clinical</subject><subject>Europe</subject><subject>Humans</subject><subject>Lymphoma - radiotherapy</subject><subject>Radioimmunotherapy - trends</subject><subject>Radiopharmaceuticals - therapeutic use</subject><issn>1506-9680</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1kE1LxDAURbNQnHH0L0hW7govaZs0Sxn8ggFB1G3JpC9OJGlqki767x1xXN0L53AX94ysWQuiUqKDFbnM-QugbThnF2TFOs47zsSafLzqwUUXwjzGcsCkp4XamKhfwnSIQdOK6lH7JbtMo6XGu9EZ7WlJTvt8ZMOxoi4Bx0K1_4zJlUPIV-TcHjlen3JD3h_u37ZP1e7l8Xl7t6smDqpUZm86hZ0dtOI4sJorKblFNMIo0aABDoYrVltpm72CBqQFBbaVWrDGCFFvyO3f7pTi94y59MFlg97rEeOcewkgG9n-ijcncd4HHPopuaDT0v8_Uf8ACllagQ</recordid><startdate>2007</startdate><enddate>2007</enddate><creator>Jurczak, Wojciech</creator><creator>Hubalewska-Dydejczyk, Alicja</creator><creator>Giza, Agnieszka</creator><creator>Sowa-Staszczak, Anna</creator><creator>Huszno, Bohdan</creator><creator>Skotnicki, Aleksander B</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>2007</creationdate><title>Radioimmunotherapy for lymphoma - analysis of clinical trials and treatment algorithms</title><author>Jurczak, Wojciech ; Hubalewska-Dydejczyk, Alicja ; Giza, Agnieszka ; Sowa-Staszczak, Anna ; Huszno, Bohdan ; Skotnicki, Aleksander B</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p209t-cbc89e8fda92ed1329772feec6c964ec020c2913f7f4b90407f090f57a614c663</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Algorithms</topic><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Clinical Trials as Topic - trends</topic><topic>Decision Support Systems, Clinical</topic><topic>Europe</topic><topic>Humans</topic><topic>Lymphoma - radiotherapy</topic><topic>Radioimmunotherapy - trends</topic><topic>Radiopharmaceuticals - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jurczak, Wojciech</creatorcontrib><creatorcontrib>Hubalewska-Dydejczyk, Alicja</creatorcontrib><creatorcontrib>Giza, Agnieszka</creatorcontrib><creatorcontrib>Sowa-Staszczak, Anna</creatorcontrib><creatorcontrib>Huszno, Bohdan</creatorcontrib><creatorcontrib>Skotnicki, Aleksander B</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Nuclear medicine review. Central & Eastern Europe</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jurczak, Wojciech</au><au>Hubalewska-Dydejczyk, Alicja</au><au>Giza, Agnieszka</au><au>Sowa-Staszczak, Anna</au><au>Huszno, Bohdan</au><au>Skotnicki, Aleksander B</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Radioimmunotherapy for lymphoma - analysis of clinical trials and treatment algorithms</atitle><jtitle>Nuclear medicine review. Central & Eastern Europe</jtitle><addtitle>Nucl Med Rev Cent East Eur</addtitle><date>2007</date><risdate>2007</risdate><volume>10</volume><issue>2</issue><spage>110</spage><epage>115</epage><pages>110-115</pages><issn>1506-9680</issn><abstract>Ibritumomab, an (90)Yttrium ((90)Y) labelled radioimmunoconjugate, is registered in Europe to treat follicular lymphomas. Its mode of action combines the selectivity of monoclonal antibodies with the efficiency of radiotherapy, making it a unique and useful therapeutic agent. This paper is for haemato-oncologists with a decent practice in lymphoma therapy, who have not yet used ibritumomab themselves. It summarizes clinical trials with radioimmunotherapy, indicating clinical situations where it may be specifically useful.</abstract><cop>Poland</cop><pmid>18228216</pmid><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1506-9680 |
| ispartof | Nuclear medicine review. Central & Eastern Europe, 2007, Vol.10 (2), p.110-115 |
| issn | 1506-9680 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_70074756 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Algorithms Antibodies, Monoclonal - therapeutic use Clinical Trials as Topic - trends Decision Support Systems, Clinical Europe Humans Lymphoma - radiotherapy Radioimmunotherapy - trends Radiopharmaceuticals - therapeutic use |
| title | Radioimmunotherapy for lymphoma - analysis of clinical trials and treatment algorithms |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T08%3A01%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Radioimmunotherapy%20for%20lymphoma%20-%20analysis%20of%20clinical%20trials%20and%20treatment%20algorithms&rft.jtitle=Nuclear%20medicine%20review.%20Central%20&%20Eastern%20Europe&rft.au=Jurczak,%20Wojciech&rft.date=2007&rft.volume=10&rft.issue=2&rft.spage=110&rft.epage=115&rft.pages=110-115&rft.issn=1506-9680&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E70074756%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=70074756&rft_id=info:pmid/18228216&rfr_iscdi=true |